Edmond DE Rothschild Holding S.A. Sells 128,428 Shares of Pfizer Inc. $PFE

Key Points

• Edmond DE Rothschild Holding cut its Pfizer position by 8.1%, selling 128,428 shares and retaining 1,455,651 shares valued at approximately $35.1 million. Institutional investors collectively own 68.36% of Pfizer.
• Analyst sentiment remains cautious, with Pfizer carrying a consensus “Hold” rating and an average price target of $28.28 after several brokerages lowered their targets.
• Pfizer exceeded quarterly earnings and revenue expectations, reporting $0.77 in EPS and $15.03 billion in revenue. The company also announced a quarterly dividend of $0.43 per share, representing a 6.1% annualized yield.

Edmond DE Rothschild Holding S.A. reduced its position in Pfizer Inc. (NYSE:PFE - Free Report) by 8.1% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 1,455,651 shares of the biopharmaceutical company's stock after selling 128,428 shares during the period. Edmond DE Rothschild Holding S.A.'s holdings in Pfizer were worth $35,052,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Vermillion Wealth Management Inc. lifted its stake in shares of Pfizer by 19.4% during the first quarter. Vermillion Wealth Management Inc. now owns 2,352 shares of the biopharmaceutical company's stock valued at $66,000 after acquiring an additional 382 shares during the period. Eagle Capital Management LLC increased its position in Pfizer by 0.3% in the first quarter. Eagle Capital Management LLC now owns 126,573 shares of the biopharmaceutical company's stock worth $3,554,000 after purchasing an additional 390 shares during the period. Delta Financial Advisors LLC increased its position in Pfizer by 1.6% in the first quarter. Delta Financial Advisors LLC now owns 25,266 shares of the biopharmaceutical company's stock worth $709,000 after purchasing an additional 398 shares during the period. Pines Wealth Management LLC raised its holdings in Pfizer by 4.4% during the 4th quarter. Pines Wealth Management LLC now owns 9,430 shares of the biopharmaceutical company's stock worth $235,000 after purchasing an additional 400 shares during the last quarter. Finally, Mount Vernon Associates Inc. MD raised its holdings in Pfizer by 1.0% during the 1st quarter. Mount Vernon Associates Inc. MD now owns 41,919 shares of the biopharmaceutical company's stock worth $1,177,000 after purchasing an additional 400 shares during the last quarter. Institutional investors own 68.36% of the company's stock.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on PFE. HSBC lowered shares of Pfizer from a "buy" rating to a "hold" rating and reduced their target price for the company from $32.00 to $28.00 in a research note on Monday, July 6th. Guggenheim cut their price objective on shares of Pfizer from $35.00 to $31.00 and set a "buy" rating on the stock in a report on Friday, August 7th. Cantor Fitzgerald reaffirmed a "neutral" rating and issued a $27.00 price objective on shares of Pfizer in a research note on Monday, July 6th. JPMorgan Chase & Co. lowered their target price on shares of Pfizer from $30.00 to $28.00 and set a "neutral" rating for the company in a report on Wednesday, July 8th. Finally, Bank of America dropped their target price on shares of Pfizer from $27.00 to $26.00 and set a "neutral" rating for the company in a research report on Friday, July 10th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, Pfizer has a consensus rating of "Hold" and an average target price of $28.28.

Pfizer Price Performance

Pfizer stock opened at $28.00 on Friday. The company has a current ratio of 1.27, a quick ratio of 0.96 and a debt-to-equity ratio of 0.71. The firm has a market capitalization of $159.59 billion, a P/E ratio of 36.84 and a beta of 0.34. The business has a 50-day moving average of $25.30 and a 200-day moving average of $26.25. Pfizer Inc. has a 1 year low of $23.58 and a 1 year high of $28.75.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share for the quarter, beating analysts' consensus estimates of $0.68 by $0.09. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The business had revenue of $15.03 billion for the quarter, compared to the consensus estimate of $14.40 billion. During the same period last year, the company posted $0.78 EPS. Pfizer's revenue for the quarter was up 2.6% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, equities analysts anticipate that Pfizer Inc. will post 2.98 EPS for the current year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th will be issued a $0.43 dividend. The ex-dividend date is Friday, July 24th. This represents a $1.72 annualized dividend and a yield of 6.1%. Pfizer's dividend payout ratio (DPR) is 226.32%.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer completed a Phase 1/2 study of PF-07868489, an experimental treatment for pulmonary arterial hypertension. The milestone supports early-stage pipeline progress, though additional clinical testing will be needed before any potential commercialization. Pfizer’s PF-07868489 PAH Study Reaches Completion
• Positive Sentiment: Several additional clinical updates highlighted progress across Pfizer’s development portfolio: completion of a Phase 1 atirmociclib study, completion of a drug-interaction study for PF-07248144, and a new Phase 1 liver study for atirmociclib. These milestones may reinforce confidence in Pfizer’s ability to replenish revenue as older products face competition. Atirmociclib Study Update PF-07248144 Study Update
• Positive Sentiment: Pfizer is also expanding real-world evidence efforts for prostate cancer therapies, Ibrance in advanced breast cancer, and a migraine treatment study in India. These studies could support broader use and strengthen commercial evidence for existing medicines. Pfizer Real-World Prostate Cancer Study
• Positive Sentiment: Investor-oriented coverage remains constructive, citing Pfizer’s roughly 19% year-to-date gain, attractive dividend yield, and reported hedge-fund buying. The stock’s move toward its 52-week high suggests improving sentiment. Hedge Funds Buying Pfizer
• Neutral Sentiment: Unusually large options activity may increase short-term trading interest, but it does not establish a clear fundamental direction for PFE. Pfizer Options Trading
• Negative Sentiment: Coverage of settlements involving thousands of Depo-Provera lawsuits raises concerns about potential legal costs and ongoing liability. Analysts also continue to weigh whether new drugs and acquisitions can offset revenue losses from expiring patents. Pfizer Legal Claims

About Pfizer

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source